Analyzing the symptoms in colorectal and breast cancer patients with or without type 2 diabetes using EHR data.
Xiao LuoSusan StoreyPriyanka GandhiZuoyi ZhangMegan MetzgerKun HuangPublished in: Health informatics journal (2021)
This research extracted patient-reported symptoms from free-text EHR notes of colorectal and breast cancer patients and studied the correlation of the symptoms with comorbid type 2 diabetes, race, and smoking status. An NLP framework was developed first to use UMLS MetaMap to extract all symptom terms from the 366,398 EHR clinical notes of 1694 colorectal cancer (CRC) patients and 3458 breast cancer (BC) patients. Semantic analysis and clustering algorithms were then developed to categorize all the relevant symptoms into eight symptom clusters defined by seed terms. After all the relevant symptoms were extracted from the EHR clinical notes, the frequency of the symptoms reported from colorectal cancer (CRC) and breast cancer (BC) patients over three time-periods post-chemotherapy was calculated. Logistic regression (LR) was performed with each symptom cluster as the response variable while controlling for diabetes, race, and smoking status. The results show that the CRC and BC patients with Type 2 Diabetes (T2D) were more likely to report symptoms than CRC and BC without T2D over three time-periods in the cancer trajectory. We also found that current smokers were more likely to report anxiety (CRC, BC), neuropathic symptoms (CRC, BC), anxiety (BC), and depression (BC) than non-smokers.
Keyphrases
- type diabetes
- patient reported
- end stage renal disease
- sleep quality
- ejection fraction
- smoking cessation
- newly diagnosed
- electronic health record
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- depressive symptoms
- machine learning
- radiation therapy
- glycemic control
- squamous cell carcinoma
- patient reported outcomes
- metabolic syndrome
- deep learning
- young adults
- big data
- artificial intelligence
- skeletal muscle
- squamous cell
- rectal cancer